interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Cefepime Hydrochloride; Zidebactam

Generic competition · all medicines · read 12 November 2026

Is there a generic of Cefepime Hydrochloride; Zidebactam, and who makes it?

Cefepime Hydrochloride; Zidebactam appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Cefepime Hydrochloride; Zidebactam1 dosage-form group in the Orange Book
0generic makers listed
  1. Cefepime Hydrochloride; Zidebactam appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Powder, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Zaynich. No generic is listed as marketed.

2020202520302035204001brand 2026data datePatent 9132133 listed to expire 24 August 2032Patent 9827235 listed to expire 24 August 2032Patent 8853197 listed to expire 24 August 2032Patent 9381200 listed to expire 24 August 2032Patent 8822450 listed to expire 24 August 2032Patent 9834557 listed to expire 12 October 2033Patent 9657021 listed to expire 12 October 2033Exclusivity NCE to 29 May 2031Exclusivity GAIN to 29 May 2036
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 29 May 2031Exclusivity NCE Zaynich
  • 29 May 2036Exclusivity GAIN Zaynich
  • 24 August 2032Patent 9132133
  • 24 August 2032Patent 9827235 drug product
  • 24 August 2032Patent 8853197 drug substance
  • 24 August 2032Patent 9381200 drug product
  • 24 August 2032Patent 8822450 drug substance
  • 12 October 2033Patent 9834557 drug substance
  • 12 October 2033Patent 9657021 drug substance

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.